MorphoSys (MOR) News Today €67.25 0.00 (0.00%) As of 08/20/2024 Add Compare Share Share Headlines Stock AnalysisHeadlines All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Novartis to close MorphoSys sites in Boston, Munich: reportDecember 19, 2024 | msn.comNovartis says 330 jobs hit as it closes MorphoSys sitesDecember 19, 2024 | msn.comNovartis raises sales guidance until 2028November 21, 2024 | msn.comAsymptomatic or Minimally Symptomatic MyelofibrosisNovember 4, 2024 | msn.comBiogen refreshes its C-suite; Novartis writes down MorphoSys assetsOctober 29, 2024 | finance.yahoo.comNovartis says more time needed for cancer therapy added with MorphoSys dealOctober 29, 2024 | msn.comJAK Inhibitors Clinical Trial Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 50+ Companies Working in the DomainOctober 22, 2024 | finance.yahoo.comERAS Sep 2024 2.500 put (ERAS240920P00002500)August 28, 2024 | finance.yahoo.comMorphoSys (ETR:MOR) Stock Price Down 0.6%MorphoSys (ETR:MOR) Shares Down 0.6%August 20, 2024 | marketbeat.comMORF Sep 2024 40.000 put (MORF240920P00040000)August 17, 2024 | finance.yahoo.comMorphoSys (ETR:MOR) Hits New 1-Year High at $68.20MorphoSys (ETR:MOR) Reaches New 12-Month High at $68.20May 23, 2024 | marketbeat.comLatest News for MorphoSys Stock (NASDAQ:MOR)May 17, 2024 | benzinga.comMorphoSys gains after Novartis discloses all tender offer conditions were metMay 16, 2024 | msn.comMorphoSys (ETR:MOR) Shares Down 0.1% MorphoSys (ETR:MOR) Trading Down 0.1%May 9, 2024 | marketbeat.comUPDATE 2-Novartis to buy radiology drug specialist Mariana for $1 billionMay 2, 2024 | finance.yahoo.comMorphoSys: Hold Rating Until The Novartis Deal ClosesApril 30, 2024 | seekingalpha.comGermany stocks mixed at close of trade; DAX down 0.16%April 29, 2024 | msn.comNew safety risk for MorphoSys drug could complicate Novartis deal - STATApril 28, 2024 | msn.comMorphoSys earnings: here's what Wall Street expectsApril 28, 2024 | markets.businessinsider.comMorphoSys To Present New Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2024 ASCO Annual MeetingApril 24, 2024 | finance.yahoo.comMorphoSys (ETR:MOR) Reaches New 12-Month High at $68.00MorphoSys (ETR:MOR) Reaches New 12-Month High at $68.00April 17, 2024 | marketbeat.comGerman biopharma MorphoSys recommends Novartis offer be acceptedApril 11, 2024 | msn.comNovartis Pharma AG: Novartis tender offer for MorphoSys AG commencesApril 11, 2024 | finanznachrichten.deNovartis tender offer for MorphoSys AG commencesApril 11, 2024 | finance.yahoo.comNovartis begins tender offer for cancer-focused MorphoSysApril 11, 2024 | msn.comNovartis commences tender offer for MorphoSysApril 11, 2024 | msn.comUPDATE 2-Novartis begins tender offer for cancer-focused MorphoSysApril 11, 2024 | finance.yahoo.comNovartis: Higher Guidance, Now A BuyApril 4, 2024 | seekingalpha.comMorphoSys (ETR:MOR) Sets New 52-Week High at $67.30MorphoSys (ETR:MOR) Hits New 52-Week High at $67.30April 2, 2024 | marketbeat.comEQS-News: MorphoSys Announces U.S. Antitrust Clearance of Proposed Acquisition by Novartis Under HSR ActMarch 22, 2024 | markets.businessinsider.comMorphoSys AG (NASDAQ:MOR) Q4 2023 Earnings Call TranscriptMarch 15, 2024 | finance.yahoo.comEQS-News: MorphoSys AG Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateMarch 13, 2024 | markets.businessinsider.comMorphoSys: Q4 Earnings InsightsMarch 13, 2024 | benzinga.comGerman regulators approve Novartis deal to buy drugmaker MorphosysMarch 12, 2024 | msn.comWhat Makes MorphoSys AG Unsponsored ADR (MOR) a Strong Momentum Stock: Buy Now?February 15, 2024 | finance.yahoo.comBiotech Stock Roundup: GILD, AMGN & BMY's Q4 Results, MOR Up on NVS Deal & MoreFebruary 8, 2024 | finance.yahoo.comMorphoSys just downgraded at JMP Securities, here's whyFebruary 7, 2024 | realmoney.thestreet.comNovartis (NVS) to Buy MorphoSys & Add Late-Stage Oncology DrugFebruary 6, 2024 | finance.yahoo.comNovartis And MorphoSys Are A Perfect MatchFebruary 6, 2024 | seekingalpha.comNovartis to strengthen oncology pipeline with agreement to acquire MorphoSys AG for EUR 68 per share or an aggregate of EUR 2.7bn in cashFebruary 5, 2024 | finance.yahoo.comUPDATE 1-Novartis to acquire cancer drug developer MorphoSys for $2.9 blnFebruary 5, 2024 | finance.yahoo.comMorphoSys AG ADR MORFebruary 3, 2024 | morningstar.comDAX Edges Higher As Investors Await GDP DataJanuary 31, 2024 | markets.businessinsider.comUS Futures Flat, European Stocks Slightly Down Ahead of Central Bank DecisionsJanuary 30, 2024 | marketwatch.comEuropean Shares Slightly Higher; Flash Eurozone GDP Data AwaitedJanuary 30, 2024 | markets.businessinsider.comMorphoSys expects 2024 Monjuvi U.S. net product sales in $80M - $95M rangeJanuary 30, 2024 | msn.comMorphoSys Reports Preliminary 2023 Monjuvi U.S. Net Product Sales and Gross Margin, Provides 2024 Financial Guidance and Reduces Financial LiabilityJanuary 30, 2024 | finance.yahoo.comMorphoSys Reports Preliminary 2023 Monjuvi U.S. Net Product Sales and Gross Margin, Provides 2024 Financial Guidance and Reduces Financial LiabilityJanuary 30, 2024 | finance.yahoo.comMorphoSys: Positive Pelabresib Data Finally Unlocking UpsideJanuary 18, 2024 | seekingalpha.comEQS-News: MorphoSys to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceJanuary 8, 2024 | markets.businessinsider.com Get MorphoSys News Delivered to You Automatically Sign up to receive the latest news and ratings for MOR and its competitors with MarketBeat's FREE daily newsletter. Email Address MOR Media Mentions By Week MOR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MOR News Sentiment▼0.000.60▲Average Medical News Sentiment MOR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MOR Articles This Week▼00▲MOR Articles Average Week Get MorphoSys News Delivered to You Automatically Sign up to receive the latest news and ratings for MOR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ad pepper media International News Today Genfit News Today Merck KGaA News Today Biotest Aktiengesellschaft News Today Medigene News Today Carl Zeiss Meditec News Today Gerresheimer News Today Evotec News Today CompuGroup Medical SE & Co. KGaA News Today Drägerwerk AG & Co. KGaA News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (ETR:MOR) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersThe Real Hillbilly ElegyThe mountains of Appalachia are incredible to behold. Spanning thousands of miles across Alabama, Kentucky...Porter & Company | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredCollect $7k per month from Tesla’s SECRET dividendThere's a little-known secret about Tesla that even seasoned investors don't know. Despite not paying a tra...Investors Alley | SponsoredElon Social Security shock?“A Maniacal Sense of Urgency” We could be just days away from Elon Musk launching his next big venture. One...Altimetry | SponsoredMajor AI announcement for 2025BIG NEWS: “Market Wizard” Larry Benedict Releases a Whole New Way to Trade AI StocksBrownstone Research | SponsoredHas Trump finally met his match?A new Chinese AI software called "DeepSeek" is sending shockwaves through the market. It's advanced enough ...Behind the Markets | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MorphoSys AG Please log in to your account or sign up in order to add this asset to your watchlist. Share MorphoSys With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
